Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research ...

X Genomics Inc . (NASDAQ:TXG) reported its Q4 2024 earnings, revealing a larger-than-expected loss per share and a decline in revenue compared to the previous year. The company posted an EPS of -$0.40 ...

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for. 10x Genomics missed analysts’ revenue expectations by 5% last quarter ...

PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial ...

TD Cowen analyst Dan Brennan lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps a Hold rating on the shares. The firm said with a 4Q revenue beat preannounced the ...

At this time, I would like to welcome everyone to the 10X Genomics fourth quarter and full year 2024 earnings conference call. (Operator Instructions). I would now like to turn the conference over ...